223 related articles for article (PubMed ID: 33918134)
21. Establishment and Reversal of HIV-1 Latency in Naive and Central Memory CD4+ T Cells In Vitro.
Zerbato JM; Serrao E; Lenzi G; Kim B; Ambrose Z; Watkins SC; Engelman AN; Sluis-Cremer N
J Virol; 2016 Sep; 90(18):8059-73. PubMed ID: 27356901
[TBL] [Abstract][Full Text] [Related]
22. Experimental approaches to the study of HIV-1 latency.
Han Y; Wind-Rotolo M; Yang HC; Siliciano JD; Siliciano RF
Nat Rev Microbiol; 2007 Feb; 5(2):95-106. PubMed ID: 17224919
[TBL] [Abstract][Full Text] [Related]
23. The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
Mousseau G; Kessing CF; Fromentin R; Trautmann L; Chomont N; Valente ST
mBio; 2015 Jul; 6(4):e00465. PubMed ID: 26152583
[TBL] [Abstract][Full Text] [Related]
24. A novel bromodomain inhibitor, CPI-203, serves as an HIV-1 latency-reversing agent by activating positive transcription elongation factor b.
Liang T; Zhang X; Lai F; Lin J; Zhou C; Xu X; Tan X; Liu S; Li L
Biochem Pharmacol; 2019 Jun; 164():237-251. PubMed ID: 30991051
[TBL] [Abstract][Full Text] [Related]
25. PIWIL4 Maintains HIV-1 Latency by Enforcing Epigenetically Suppressive Modifications on the 5' Long Terminal Repeat.
He Z; Jing S; Yang T; Chen J; Huang F; Zhang W; Peng Z; Liu B; Ma X; Wu L; Pan T; Zhang X; Li L; Cai W; Tang X; Zhang J; Zhang H
J Virol; 2020 May; 94(10):. PubMed ID: 32161174
[TBL] [Abstract][Full Text] [Related]
26. A CCR5
Terahara K; Iwabuchi R; Hosokawa M; Nishikawa Y; Takeyama H; Takahashi Y; Tsunetsugu-Yokota Y
BMC Res Notes; 2019 Apr; 12(1):242. PubMed ID: 31036079
[TBL] [Abstract][Full Text] [Related]
27. Targeting HIV latency: resting memory T cells, hematopoietic progenitor cells and future directions.
Sebastian NT; Collins KL
Expert Rev Anti Infect Ther; 2014 Oct; 12(10):1187-201. PubMed ID: 25189526
[TBL] [Abstract][Full Text] [Related]
28. Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue.
Biancotto A; Grivel JC; Gondois-Rey F; Bettendroffer L; Vigne R; Brown S; Margolis LB; Hirsch I
J Virol; 2004 Oct; 78(19):10507-15. PubMed ID: 15367617
[TBL] [Abstract][Full Text] [Related]
29. Control of HIV latency by epigenetic and non-epigenetic mechanisms.
Mbonye U; Karn J
Curr HIV Res; 2011 Dec; 9(8):554-67. PubMed ID: 22211660
[TBL] [Abstract][Full Text] [Related]
30. Transcriptomic Analysis Implicates the p53 Signaling Pathway in the Establishment of HIV-1 Latency in Central Memory CD4 T Cells in an In Vitro Model.
White CH; Moesker B; Beliakova-Bethell N; Martins LJ; Spina CA; Margolis DM; Richman DD; Planelles V; Bosque A; Woelk CH
PLoS Pathog; 2016 Nov; 12(11):e1006026. PubMed ID: 27898737
[TBL] [Abstract][Full Text] [Related]
31. Modeling HIV-1 Latency Using Primary CD4
Takata H; Kessing C; Sy A; Lima N; Sciumbata J; Mori L; Jones RB; Chomont N; Michael NL; Valente S; Trautmann L
J Virol; 2019 Jun; 93(11):. PubMed ID: 30918072
[TBL] [Abstract][Full Text] [Related]
32. Heat Shock Protein 90 Facilitates Latent HIV Reactivation through Maintaining the Function of Positive Transcriptional Elongation Factor b (p-TEFb) under Proteasome Inhibition.
Pan XY; Zhao W; Wang CY; Lin J; Zeng XY; Ren RX; Wang K; Xun TR; Shai Y; Liu SW
J Biol Chem; 2016 Dec; 291(50):26177-26187. PubMed ID: 27799305
[TBL] [Abstract][Full Text] [Related]
33. Limitations of dual-fluorescent HIV reporter viruses in a model of pre-activation latency.
Kim Y; Cameron PU; Lewin SR; Anderson JL
J Int AIDS Soc; 2019 Dec; 22(12):e25425. PubMed ID: 31855322
[TBL] [Abstract][Full Text] [Related]
34. A novel in vitro system to generate and study latently HIV-infected long-lived normal CD4+ T-lymphocytes.
Sahu GK; Lee K; Ji J; Braciale V; Baron S; Cloyd MW
Virology; 2006 Nov; 355(2):127-37. PubMed ID: 16919704
[TBL] [Abstract][Full Text] [Related]
35. Activation of the Anti-Oxidative Stress Response Reactivates Latent HIV-1 Through the Mitochondrial Antiviral Signaling Protein Isoform MiniMAVS.
Sarabia I; Novis CL; Macedo AB; Takata H; Nell R; Kakazu JC; Furler RL; Shakya B; Schubert HL; Hill CP; DePaula-Silva AB; Spivak AM; Trautmann L; Planelles V; Bosque A
Front Immunol; 2021; 12():682182. PubMed ID: 34194436
[TBL] [Abstract][Full Text] [Related]
36. Apobec3A maintains HIV-1 latency through recruitment of epigenetic silencing machinery to the long terminal repeat.
Taura M; Song E; Ho YC; Iwasaki A
Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2282-2289. PubMed ID: 30670656
[TBL] [Abstract][Full Text] [Related]
37. HIV integration and the establishment of latency in CCL19-treated resting CD4(+) T cells require activation of NF-κB.
Saleh S; Lu HK; Evans V; Harisson D; Zhou J; Jaworowski A; Sallmann G; Cheong KY; Mota TM; Tennakoon S; Angelovich TA; Anderson J; Harman A; Cunningham A; Gray L; Churchill M; Mak J; Drummer H; Vatakis DN; Lewin SR; Cameron PU
Retrovirology; 2016 Jul; 13(1):49. PubMed ID: 27459960
[TBL] [Abstract][Full Text] [Related]
38. The sounds of silencing: dynamic epigenetic control of HIV latency.
Nguyen K; Karn J
Curr Opin HIV AIDS; 2024 May; 19(3):102-109. PubMed ID: 38547337
[TBL] [Abstract][Full Text] [Related]
39. Transcriptional Reprogramming during Effector-to-Memory Transition Renders CD4
Shan L; Deng K; Gao H; Xing S; Capoferri AA; Durand CM; Rabi SA; Laird GM; Kim M; Hosmane NN; Yang HC; Zhang H; Margolick JB; Li L; Cai W; Ke R; Flavell RA; Siliciano JD; Siliciano RF
Immunity; 2017 Oct; 47(4):766-775.e3. PubMed ID: 29045905
[TBL] [Abstract][Full Text] [Related]
40. The Pathway To Establishing HIV Latency Is Critical to How Latency Is Maintained and Reversed.
Rezaei SD; Lu HK; Chang JJ; Rhodes A; Lewin SR; Cameron PU
J Virol; 2018 Jul; 92(13):. PubMed ID: 29643247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
